Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Descending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00093-0220-56 00093-0220 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 Oct. 31, 2019 No Longer Used
00093-0220-01 00093-0220 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 Oct. 31, 2019 No Longer Used
00089-0610-12 00089-0610 Imiquimod Aldara Immunotherapy Immunomodulator Dermatological Agent Topical June 24, 2011 Jan. 31, 2015 No Longer Used
00088-1209-26 00088-1209 Dolasetron mesylate Anzemet 500.0 mg/25mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 11, 1997 June 30, 2016 No Longer Used
00088-1208-76 00088-1208 Dolasetron mesylate Anzemet 12.5 mg/.625mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 11, 1997 Nov. 9, 2012 No Longer Used
00088-1208-06 00088-1208 Dolasetron mesylate Anzemet 12.5 mg/.625mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 11, 1997 Aug. 31, 2016 No Longer Used
00088-1206-32 00088-1206 Dolasetron mesylate Anzemet 100.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 11, 1997 Sept. 30, 2017 No Longer Used
00088-1203-43 00088-1203 Dolasetron mesylate Anzemet 100.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 11, 1997 Oct. 31, 2012 No Longer Used
00088-1203-29 00088-1203 Dolasetron mesylate Anzemet 100.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 11, 1997 March 31, 2006 No Longer Used
00088-1203-05 00088-1203 Dolasetron mesylate Anzemet 100.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 11, 1997 June 30, 2017 No Longer Used
00088-1202-43 00088-1202 Dolasetron mesylate Anzemet 50.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 11, 1997 Aug. 31, 2011 No Longer Used
00088-1202-05 00088-1202 Dolasetron mesylate Anzemet 50.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 11, 1997 June 30, 2017 No Longer Used
00088-1111-14 00088-1111 Nilutamide Nilandron 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Sept. 19, 1996 March 31, 2015 No Longer Used
00085-4352-01 00085-4352 Interferon alfa-2b Intron A Immunotherapy Cytokine Interferon Aug. 11, 2014 In Use
00085-4351-01 00085-4351 Interferon alfa-2b Intron A Immunotherapy Cytokine Interferon Aug. 11, 2014 In Use
00085-4350-01 00085-4350 Interferon alfa-2b Intron A Immunotherapy Cytokine Interferon Aug. 11, 2014 In Use
00085-4349-01 00085-4349 Peginterferon alfa-2b Sylatron Immunotherapy Cytokine Interferon March 29, 2011 Oct. 18, 2020 In Use
00085-4348-01 00085-4348 Peginterferon alfa-2b Sylatron Immunotherapy Cytokine Interferon March 29, 2011 Oct. 18, 2020 In Use
00085-4347-01 00085-4347 Peginterferon alfa-2b Sylatron Immunotherapy Cytokine Interferon Aug. 30, 2014 Oct. 18, 2020 In Use
00085-3004-05 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-3004-04 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-3004-03 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-3004-02 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-3004-01 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-1519-05 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use

Found 10,000 results in 12 millisecondsExport these results